Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

17th August 2018 (Last Updated August 12th, 2019 10:38)

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13 a share.

The underwriters will have a 30-day option to buy an additional 0.3 million shares of the company’s common stock.

Based in the US, Aridis is a biopharmaceutical company focused on the development of innovative therapies for infectious diseases.

Maxim Group has been appointed as the lead manager, while Laidlaw & Company (UK), Northland Securities and Seaport Global Securities are acting as co-managers to Aridis for the offering.

Xeris Pharmaceuticals has raised $98.3m through an initial public offering of 6.5 million shares of its common stock priced at $15 a share.

The underwriters will have a 30-day option to buy an additional 0.85 million shares of the company’s common stock.

Based in the US, Xeris is a speciality pharmaceutical company engaged in the development and commercialisation of room-temperature stable injectable and infusible drug formulations.

Jefferies, Leerink Partners, RBC Capital Markets and Mizuho Securities were appointed as the joint book running managers to the company for the offering.

Astellas Pharma has completed the acquisition of UK-based gene therapy company Quethera for $108.5m.

Quethera will receive £85m ($108.5m) in upfront and contingent payments from Astellas, as part of the transaction.

"Xeris Pharmaceuticals has raised $98.3m through an initial public offering of 6.5 million shares of its common stock priced at $15 a share."

The acquisition includes Quethera’s ophthalmic gene therapy programme, which will be a complementary addition to Astellas’ portfolio.

Based in Japan, Astellas is a pharmaceutical company offering products for several therapeutic areas such as cardiology, dermatology, oncology, and urology.

The deal enables the acquirer company to accelerate the development of investigational technology programme to prevent disease progression in patients suffering from serious diseases.

Emergent BioSolutions has entered an agreement to acquire PaxVax for $270m in cash.

The transaction includes US FDA licensed Vivotif vaccine indicated for the treatment of typhoid fever, and Vaxchora, a vaccine used for the prevention of cholera. In addition, the purchase includes the target company’s European biologics manufacturing.

Based in the US, Emergent BioSolutions is engaged in the development and commercialisation of immunobiotics such as vaccines and immune globulins, while PaxVax, also based in the US, is a manufacturer of vaccines for various infectious diseases.

The transaction will enable Emergent BioSolutions to diversify its customer base and international reach and boost its contract development and manufacturing capabilities.